The therapeutic effect of combining an anti-EGFR antibody (cetuximab) with an anti-PD-L1 antibody (avelumab) varies in patients with mCRC and non-small cell lung cancer (NSCLC) depending on specific microbiome compositions [71]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.